Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA.
Emory University, Atlanta, GA, USA.
J Natl Cancer Inst Monogr. 2024 Aug 1;2024(65):168-179. doi: 10.1093/jncimonographs/lgae013.
Precision medicine has become a mainstay of cancer care in recent years. The National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program has been an authoritative source of cancer statistics and data since 1973. However, tumor genomic information has not been adequately captured in the cancer surveillance data, which impedes population-based research on molecular subtypes. To address this, the SEER Program has developed and implemented a centralized process to link SEER registries' tumor cases with genomic test results that are provided by molecular laboratories to the registries.
Data linkages were carried out following operating procedures for centralized linkages established by the SEER Program. The linkages used Match*Pro, a probabilistic linkage software, and were facilitated by the registries' trusted third party (an honest broker). The SEER registries provide to NCI limited datasets that undergo preliminary evaluation prior to their release to the research community.
Recently conducted genomic linkages included OncotypeDX Breast Recurrence Score, OncotypeDX Breast Ductal Carcinoma in Situ, OncotypeDX Genomic Prostate Score, Decipher Prostate Genomic Classifier, DecisionDX Uveal Melanoma, DecisionDX Preferentially Expressed Antigen in Melanoma, DecisionDX Melanoma, and germline tests results in Georgia and California SEER registries.
The linkages of cancer cases from SEER registries with genomic test results obtained from molecular laboratories offer an effective approach for data collection in cancer surveillance. By providing de-identified data to the research community, the NCI's SEER Program enables scientists to investigate numerous research inquiries.
近年来，精准医学已成为癌症治疗的主要手段。自 1973 年以来，美国国家癌症研究所（NCI）的监测、流行病学和最终结果（SEER）计划一直是癌症统计数据和信息的权威来源。然而，肿瘤基因组信息在癌症监测数据中并未得到充分捕获，这阻碍了基于人群的分子亚型研究。为了解决这个问题，SEER 计划已经开发并实施了一个集中的流程，将 SEER 登记处的肿瘤病例与分子实验室提供给登记处的基因组测试结果进行链接。
数据链接是按照 SEER 计划建立的集中链接操作程序进行的。链接使用了 Match*Pro，这是一种概率链接软件，并由登记处的可信第三方（诚实经纪人）提供便利。SEER 登记处向 NCI 提供有限的数据集，这些数据集在向研究界发布之前会经过初步评估。
最近进行的基因组链接包括 OncotypeDX 乳腺癌复发评分、OncotypeDX 乳腺导管原位癌、OncotypeDX 前列腺基因组评分、Decipher 前列腺基因组分类器、DecisionDX 葡萄膜黑色素瘤、DecisionDX 黑色素瘤优先表达抗原、DecisionDX 黑色素瘤以及佐治亚州和加利福尼亚州 SEER 登记处的种系测试结果。
SEER 登记处的癌症病例与从分子实验室获得的基因组测试结果的链接为癌症监测中的数据收集提供了一种有效方法。通过向研究界提供去识别数据，NCI 的 SEER 计划使科学家能够进行许多研究调查。
